for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MediciNova, Inc.

MNOV.OQ

Latest Trade

5.89USD

Change

-0.04(-0.67%)

Volume

37,220

Today's Range

5.68

 - 

5.96

52 Week Range

2.79

 - 

13.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.93
Open
5.95
Volume
37,220
3M AVG Volume
10.17
Today's High
5.96
Today's Low
5.68
52 Week High
13.25
52 Week Low
2.79
Shares Out (MIL)
44.93
Market Cap (MIL)
266.42
Forward P/E
-17.32
Dividend (Yield %)
--

Next Event

Q4 2020 MediciNova Inc Earnings Release

Latest Developments

More

Medicinova, In Collaboration With The University Of Sydney And The Australasian Gastro-Intestinal Trials Group, Announces Plans For A Multi-Center, Phase 2B Study To Evaluate Mn-166 In Chemother

MediciNova Announces Development Progress On Intranasal Formulation Of Sars-Cov-2 Vaccine For Covid-19

Medicinova Named Edward Stepanow, Jr. Of Signature Analytics As CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MediciNova, Inc.

Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Industry

Biotechnology & Drugs

Contact Info

4275 Executive Sq Ste 300

LA JOLLA, CA

92037-8408

United States

+1.858.3731500

https://medicinova.com/

Executive Leadership

Jeffrey Himawan

Independent Chairman of the Board

Yuichi Iwaki

President, Chief Executive Officer, Director

Edward Stepanow

Chief Financial Officer

Geoffrey G. O'brien

Vice President

Kazuko Matsuda

Chief Medical Officer, Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.320

2018

-0.360

2019

-0.300

2020(E)

-0.340
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-16.91
Return on Equity (TTM)
-16.53

Latest News

Latest News

BRIEF-Medicinova Inc - IND For Ibudilast Has Been Accepted And Is Now Open With FDA

* MEDICINOVA INC - IND) FOR MN-166 (IBUDILAST) FOR PREVENTION OF ACUTE RESPIRATORY DISTRESS SYNDROME HAS BEEN ACCEPTED AND IS NOW OPEN WITH FDA

BRIEF-Medicinova Announces Positive Preclinical Results Of Mn-166 In Glioblastoma Published In Frontiers In Immunology

* MEDICINOVA ANNOUNCES POSITIVE PRECLINICAL RESULTS REGARDING MN-166 (IBUDILAST) IN GLIOBLASTOMA (GBM) PUBLISHED IN FRONTIERS IN IMMUNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Medicinova Announces Plans To Initiate A Clinical Trial Of Mn-166 For Covid-19 Acute Respiratory Distress Syndrome

* MEDICINOVA ANNOUNCES PLANS TO INITIATE A CLINICAL TRIAL OF MN-166 (IBUDILAST) FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Medicinova Plans To Start MN-166 Development For Severe Pneumonia And Acute Respiratory Distress Syndrome

* PLANS TO INITIATE DEVELOPMENT OF MN-166 (IBUDILAST) FOR SEVERE PNEUMONIA AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). Source text for Eikon: Further company coverage:

BRIEF-Medicinova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For Treatment Of Advanced NASH In Japan

* MEDICINOVA RECEIVES NOTICE OF ALLOWANCE FOR NEW PATENT COVERING MN-001 AND MN-002 FOR THE TREATMENT OF ADVANCED NASH IN JAPAN

BRIEF-MediciNova to collaborate with UCLA researchers in grant-funded clinical trial of MN-166 (ibudilast) in alcohol use disorder and withdrawal

* Says it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA)

BRIEF-MediciNova Announces Proposed Underwritten Public Offering

* MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Medicinova Announces Phase 2B Trial results in MN-166 (Ibudilast)

* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) DEMONSTRATED A 26 PCT REDUCTION IN CONFIRMED DISABILITY PROGRESSION IN THE SPRINT-MS PHASE 2B TRIAL IN PROGRESSIVE MS: POTENTIAL BEST-IN-DISEASE DRUG Source text for Eikon: Further company coverage:

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up